Cargando…
Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
BACKGROUND: We previously reported that a high tumor burden is a prognostic factor based on an analysis of 26 patients with radioactive iodine-refractory differentiated thyroid cancer (RR-DTC) who were treated with lenvatinib. However, the optimal tumor burden for starting lenvatinib still remains t...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298753/ https://www.ncbi.nlm.nih.gov/pubmed/34307122 http://dx.doi.org/10.3389/fonc.2021.638123 |
_version_ | 1783726118407241728 |
---|---|
author | Suzuki, Chiaki Kiyota, Naomi Imamura, Yoshinori Goto, Hideaki Suto, Hirotaka Chayahara, Naoko Toyoda, Masanori Ito, Yasuhiro Miya, Akihiro Miyauchi, Akira Teshima, Masanori Otsuki, Naoki Nibu, Ken-ichi Minami, Hironobu |
author_facet | Suzuki, Chiaki Kiyota, Naomi Imamura, Yoshinori Goto, Hideaki Suto, Hirotaka Chayahara, Naoko Toyoda, Masanori Ito, Yasuhiro Miya, Akihiro Miyauchi, Akira Teshima, Masanori Otsuki, Naoki Nibu, Ken-ichi Minami, Hironobu |
author_sort | Suzuki, Chiaki |
collection | PubMed |
description | BACKGROUND: We previously reported that a high tumor burden is a prognostic factor based on an analysis of 26 patients with radioactive iodine-refractory differentiated thyroid cancer (RR-DTC) who were treated with lenvatinib. However, the optimal tumor burden for starting lenvatinib still remains to be defined. The aim of this retrospective study was to further explore in the same patient cohort the optimal timing for the start of lenvatinib by focusing on the pre- and post-treatment tumor burden. METHODS: The 26 patients were treated with lenvatinib from 2012 to 2017. We explored the optimal timing for the start of lenvatinib by comparing the characteristics of long-term responders who were defined as patients with progression-free survival ≥ 30 months and non-long-term responders. RESULTS: Long-term responders had a smaller post-treatment tumor burden at maximum shrinkage than non-long-term responders. Further, post-treatment tumor burden had a strong linear correlation with baseline tumor burden. We created an estimation formula for baseline tumor burden related to prognosis, using these regression lines. Patients with a sum of diameters of target lesions < 60 mm or maximum tumor diameter < 34 mm at baseline were estimated to have significantly better survival outcomes. CONCLUSIONS: We found a strong linear correlation between pre- and post-treatment tumor burden. Our results suggested a cut-off value for baseline tumor burden for long-term prognosis among patients treated with lenvatinib. |
format | Online Article Text |
id | pubmed-8298753 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82987532021-07-24 Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Suzuki, Chiaki Kiyota, Naomi Imamura, Yoshinori Goto, Hideaki Suto, Hirotaka Chayahara, Naoko Toyoda, Masanori Ito, Yasuhiro Miya, Akihiro Miyauchi, Akira Teshima, Masanori Otsuki, Naoki Nibu, Ken-ichi Minami, Hironobu Front Oncol Oncology BACKGROUND: We previously reported that a high tumor burden is a prognostic factor based on an analysis of 26 patients with radioactive iodine-refractory differentiated thyroid cancer (RR-DTC) who were treated with lenvatinib. However, the optimal tumor burden for starting lenvatinib still remains to be defined. The aim of this retrospective study was to further explore in the same patient cohort the optimal timing for the start of lenvatinib by focusing on the pre- and post-treatment tumor burden. METHODS: The 26 patients were treated with lenvatinib from 2012 to 2017. We explored the optimal timing for the start of lenvatinib by comparing the characteristics of long-term responders who were defined as patients with progression-free survival ≥ 30 months and non-long-term responders. RESULTS: Long-term responders had a smaller post-treatment tumor burden at maximum shrinkage than non-long-term responders. Further, post-treatment tumor burden had a strong linear correlation with baseline tumor burden. We created an estimation formula for baseline tumor burden related to prognosis, using these regression lines. Patients with a sum of diameters of target lesions < 60 mm or maximum tumor diameter < 34 mm at baseline were estimated to have significantly better survival outcomes. CONCLUSIONS: We found a strong linear correlation between pre- and post-treatment tumor burden. Our results suggested a cut-off value for baseline tumor burden for long-term prognosis among patients treated with lenvatinib. Frontiers Media S.A. 2021-07-08 /pmc/articles/PMC8298753/ /pubmed/34307122 http://dx.doi.org/10.3389/fonc.2021.638123 Text en Copyright © 2021 Suzuki, Kiyota, Imamura, Goto, Suto, Chayahara, Toyoda, Ito, Miya, Miyauchi, Teshima, Otsuki, Nibu and Minami https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Suzuki, Chiaki Kiyota, Naomi Imamura, Yoshinori Goto, Hideaki Suto, Hirotaka Chayahara, Naoko Toyoda, Masanori Ito, Yasuhiro Miya, Akihiro Miyauchi, Akira Teshima, Masanori Otsuki, Naoki Nibu, Ken-ichi Minami, Hironobu Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer |
title | Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer |
title_full | Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer |
title_fullStr | Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer |
title_full_unstemmed | Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer |
title_short | Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer |
title_sort | exploratory analysis to predict optimal tumor burden for starting lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298753/ https://www.ncbi.nlm.nih.gov/pubmed/34307122 http://dx.doi.org/10.3389/fonc.2021.638123 |
work_keys_str_mv | AT suzukichiaki exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer AT kiyotanaomi exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer AT imamurayoshinori exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer AT gotohideaki exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer AT sutohirotaka exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer AT chayaharanaoko exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer AT toyodamasanori exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer AT itoyasuhiro exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer AT miyaakihiro exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer AT miyauchiakira exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer AT teshimamasanori exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer AT otsukinaoki exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer AT nibukenichi exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer AT minamihironobu exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer |